|
4 Companies |
|
3 Products |
|
3 Products |
|
8 Mechanisms of Action |
|
0 Trials |
|
10 News |
|
- | NN1213 / Novo Nordisk
Trial completion, Nontuberculous mycobacteria: Adjuvant Cytokine Therapy to Treat Pulmonary Mycobacterium Avium Complex Infection (clinicaltrials.gov) - Jun 30, 2017
P1, N=2, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed
- |||| clarithromycin / Generic mfg.
Trial completion, Trial primary completion date, Nontuberculous mycobacteria: Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM) (clinicaltrials.gov) - May 22, 2017
P4, N=210, Completed, Sponsor: The University of Texas Health Science Center at Tyler
Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Nov 2010 --> Nov 2006
- |||| azithromycin / Generic mfg.
Trial completion, Trial primary completion date: Azithromycin in the Treatment of M. Avium Complex Lung Disease (clinicaltrials.gov) - May 22, 2017
P4, N=66, Completed, Sponsor: The University of Texas Health Science Center at Tyler
Active, not recruiting --> Completed | Trial primary completion date: Nov 2010 --> Nov 2006 Active, not recruiting --> Completed | Trial primary completion date: Aug 2010 --> May 2008
- |||| Mycobutin (rifabutin) / Pfizer, Lupin
Trial completion, Trial primary completion date: Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease (clinicaltrials.gov) - May 22, 2017
P4, N=58, Completed, Sponsor: The University of Texas Health Science Center at Tyler
Active, not recruiting --> Completed | Trial primary completion date: Aug 2010 --> May 2008 Active, not recruiting --> Completed | Trial primary completion date: Nov 2010 --> Nov 2006
- |||| Mycobutin (rifabutin) / Pfizer, Lupin
Trial completion, Trial primary completion date: Use of Clarithromycin and Rifabutin for the Treatment of M. Avium Complex (MAC) Lung Disease (clinicaltrials.gov) - May 22, 2017
P4, N=89, Completed, Sponsor: The University of Texas Health Science Center at Tyler
Active, not recruiting --> Completed | Trial primary completion date: Nov 2010 --> Nov 2006 Active, not recruiting --> Completed | Trial primary completion date: Jul 2010 --> Aug 2002
- ondansetron / Generic mfg.
Trial withdrawal: ITT-MAC: Improving Tolerance of Treatment of Pulmonary MAC Infections (clinicaltrials.gov) - Apr 1, 2013
P2, N=0, Withdrawn, Sponsor: University of Florida
Active, not recruiting --> Completed | Trial primary completion date: Jul 2010 --> Aug 2002 Recruiting --> Withdrawn
- ondansetron / Generic mfg.
Enrollment change: ITT-MAC: Improving Tolerance of Treatment of Pulmonary MAC Infections (clinicaltrials.gov) - Apr 1, 2013
P2, N=0, Withdrawn, Sponsor: University of Florida
Recruiting --> Withdrawn N=32 --> 0
- ondansetron / Generic mfg.
New P2 trial: ITT-MAC: Improving Tolerance of Treatment of Pulmonary MAC Infections (clinicaltrials.gov) - Oct 30, 2012
P2, N=0, Withdrawn, Sponsor: University of Florida
- azithromycin / Generic mfg.
Trial completion: Long-Term Assessment for Metabolic, Cardiovascular and Neurologic Problems in HIV-Infected Patients With Increased CD4 Cells Counts Following Anti-HIV Therapy (clinicaltrials.gov) - Oct 23, 2012
P=N/A, N=636, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=32 --> 0 Active, not recruiting --> Completed
- | Trial completion: Mycobacterium Avium Intracellulare Complex (MAC) Study (clinicaltrials.gov) - Jul 26, 2012
P=N/A, N=15, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Active, not recruiting --> Completed